Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosrolapitant and Palonosetron for Prevention of Nausea and Vomiting Induced by Highly Emetogenic ADC Therapy
NCT07841210Phase 2Active, not recruiting
- Start
- Sep 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of fosrolapitant, palonosetron in nausea ((none)), Vomiting. Started Sep 2026; status: active, not recruiting.
02
Drugs
fosrolapitantpalonosetron
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT07841210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841210.